Analysts Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $9.00

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been given a consensus rating of “Hold” by the nine ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $9.00.

Several research analysts have recently weighed in on INO shares. Citigroup reiterated a “market outperform” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, November 4th. Zacks Research lowered Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. HC Wainwright reiterated a “neutral” rating and issued a $3.00 price target on shares of Inovio Pharmaceuticals in a research report on Thursday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a report on Monday, December 1st. Finally, UBS Group restated an “overweight” rating on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th.

Inovio Pharmaceuticals Stock Up 1.0%

Shares of INO stock opened at $2.09 on Friday. The firm has a market cap of $139.47 million, a P/E ratio of -0.81 and a beta of 1.54. The company has a 50 day moving average of $2.21 and a 200-day moving average of $2.05. Inovio Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $4.44.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.07. As a group, equities analysts expect that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several hedge funds have recently bought and sold shares of INO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 5,894 shares in the last quarter. Bank of Montreal Can raised its position in shares of Inovio Pharmaceuticals by 23.7% in the second quarter. Bank of Montreal Can now owns 57,946 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 11,110 shares in the last quarter. MCF Advisors LLC bought a new stake in Inovio Pharmaceuticals during the third quarter valued at $26,000. SG Americas Securities LLC bought a new stake in Inovio Pharmaceuticals during the third quarter valued at $27,000. Finally, Stephens Inc. AR bought a new position in Inovio Pharmaceuticals in the 3rd quarter worth about $32,000. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.